Company intelligence / Profile preview

Escalier Biosciences

Nijmegen, Gelderland, Netherlandsforbion.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Escalier Biosciences develops novel small molecule therapeutics targeting the nuclear hormone receptor RORγt, a master regulator of Th17 cell differentiation and IL‑17 production. Their lead candidate ESR‑114 has completed a Phase 1/2a proof-of-concept study as a topical gel for plaque psoriasis, demonstrating safety and preliminary efficacy. The company’s approach aims to provide both topical and oral options for mild-to-severe psoriasis patients by maximizing local target engagement while minimizing systemic side effects through proprietary drug delivery technology.

Therapeutic areas: ImmunologyDermatology
Modalities: Small molecules (specifically RORγt inverse agonists)
Industry: Biotech

Drug pipeline

1 asset

ESR-114

Beyond the preview

Go deeper on Escalier Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Escalier Biosciences.

Explore the full profile